BioInvent International AB (OTCPK:BOVNF)
$ 4.7 0 (0%) Market Cap: 268.98 Mil Enterprise Value: 170.35 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 59/100

Full Year 2022 BioInvent International AB Earnings Call Transcript

Feb 22, 2023 / 01:00PM GMT
Release Date Price: $4.7
Martin Welschof
BioInvent International AB - CEO

Thank you very much, and welcome, everybody, to our call. And we'll ride jump into the first slide. So CEO, Martin Welschof, the CEO; and Stefan Ericsson, the CFO.

Our forward-looking statement and then the summary. So basically, I just want to go briefly through the events during the fourth quarter.

We started our Phase 1 trial with the subcutaneous formulation of the BI-1206. Then we received notice of allowance in the US for quite important patent covering BI-1206 and BI-1607. And then as I will show you later, we have strong progress in clinical and preclinical projects. So our pipeline is growing basically forward as projected and planned. And that was also covered during our R&D Day that we had in December 2022 in Stockholm.

And then, the other thing that we also we're quite proud about was that BioInvent and Transgene had a joint paper on BT-001, which is our joint collaboration. We won the JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022. And then we also received last but not least, IND FDA approval

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot